Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

4.2%

1 terminated/withdrawn out of 24 trials

Success Rate

95.7%

+9.1% vs industry average

Late-Stage Pipeline

25%

6 trials in Phase 3/4

Results Transparency

55%

12 of 22 completed trials have results

Key Signals

1 recruiting12 with results

Enrollment Performance

Analytics

Phase 2
10(45.5%)
Phase 3
6(27.3%)
N/A
3(13.6%)
Phase 1
3(13.6%)
22Total
Phase 2(10)
Phase 3(6)
N/A(3)
Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (24)

Showing 20 of 24 trials
NCT06223360Phase 2Recruiting

A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)

Role: lead

NCT03919162Phase 2Terminated

A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD

Role: collaborator

NCT05350410Not ApplicableCompleted

"Healthy Actions and Lifestyles to Avoid Dementia or Hispanos y el ALTo a la Demencia Program"

Role: lead

NCT03605667Phase 2Completed

Study of BHV-4157 in Alzheimer's Disease

Role: collaborator

NCT02925650Phase 1Completed

Safety, Tolerability, PK and PD of Posiphen® in Subjects With Early Alzheimer's Disease

Role: collaborator

NCT02814526Not ApplicableCompleted

Exercise in Adults With Mild Memory Problems

Role: lead

NCT03710642Phase 2Completed

Prazosin for Agitation in Alzheimer's Disease

Role: lead

NCT02738450Phase 1Completed

Safety, Tolerability and Immunogenicity of ACI-24 Vaccine in Adults With Down Syndrome

Role: collaborator

NCT00818662Phase 3Completed

A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease

Role: collaborator

NCT00876863Phase 2Completed

Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease

Role: collaborator

NCT02079909Phase 2Completed

Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease (US202)

Role: collaborator

NCT00566397Phase 2Completed

A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease

Role: collaborator

NCT01504854Phase 2Completed

Resveratrol for Alzheimer's Disease

Role: lead

NCT00440050Phase 3Completed

DHA (Docosahexaenoic Acid), an Omega 3 Fatty Acid, in Slowing the Progression of Alzheimer's Disease

Role: lead

NCT00071721Phase 3Completed

Valproate in Dementia (VALID)

Role: lead

NCT01078636Completed

Alzheimer's Disease Neuroimaging Initiative Grand Opportunity

Role: lead

NCT00546767Not ApplicableCompleted

Home-Based Assessment for Alzheimer Disease Prevention

Role: lead

NCT00106899Completed

ADNI: Alzheimer's Disease Neuroimaging Initiative

Role: lead

NCT00000173Phase 3Completed

Memory Impairment Study (Mild Cognitive Impairment Study)

Role: collaborator

NCT00004845Phase 2Completed

A Multicenter Trial of Rofecoxib and Naproxen in Alzheimer's Disease (NSAID Study)

Role: collaborator